Key result
TYRX envelope proves cost-saving and more effective for ICD/CRT-D implants, yielding ~£21,768 per QALY for CRT-Ps.
Why the study?
Is the TYRX absorbable antibacterial envelope cost-effective compared to standard of care for preventing infection in patients receiving cardiovascular implantable electronic devices?
Is the TYRX absorbable antibacterial envelope cost-effective compared to standard of care for preventing infection in patients receiving cardiovascular implantable electronic devices?
The TYRX antibacterial envelope is a cost-effective option for preventing post-operative infection in high-risk CIED patients from a UK NHS perspective.
Answers are grounded in this paper and cite their sources.
May support TYRX consideration above infection thresholds from UK NHS perspective; leaves open prospective validation before broader adoption.
AIMS: Infection is a major complication of cardiovascular implantable electronic device (CIED) therapy that usually requires device extraction and is associated with increased morbidity and mortality. The TYRX Antibacterial Envelope is a polypropylene mesh that stabilizes the CIED and elutes minocycline and rifampin to reduce the risk of post-operative infection. METHODS: A decision tree was developed to assess the cost-effectiveness of TYRX vs standard of care (SOC) following implantation of four CIED device types. The model was parameterized for a UK National Health Service perspective. Probabilities were derived from the literature. Resource use included drug acquisition and administration, hospitalization, adverse events, device extraction, and replacement. Incremental cost-effectiveness ratios (ICERs) were calculated from costs and quality-adjusted life-years (QALYs). RESULTS: Over a 12-month time horizon, TYRX was less costly and more effective than SOC when utilized in patients with an ICD or CRT-D. TYRX was associated with ICERs of £46,548 and £21,768 per QALY gained in patients with an IPG or CRT-P, respectively. TYRX was cost-effective at a £30,000 threshold at baseline probabilities of infection exceeding 1.65% (CRT-D), 1.95% (CRT-P), 1.87% (IPG), and 1.38% (ICD). LIMITATIONS AND CONCLUSIONS: Device-specific infection rates for high-risk patients were not available in the literature and not used in this analysis, potentially under-estimating the impact of TYRX in certain devices. Nevertheless, TYRX is associated with a reduction in post-operative infection risk relative to SOC, resulting in reduced healthcare resource utilization at an initial cost. The ICERs are below the accepted willingness-to-pay thresholds used by UK decision-makers. TYRX, therefore, represents a cost-effective prevention option for CIED patients at high-risk of post-operative infection.
No takes yet. Share an insight, caveat, or question.
Kay et al. (2017) studied Cardiovascular implantable electronic device (CIED) infection. TYRX Antibacterial Envelope vs. Standard of care (SOC) was evaluated on Incremental cost-effectiveness ratios (ICERs) and quality-adjusted life-years (QALYs).
Synapse has enriched 10 related papers. Consider them for comparative context: